Zydus Pharma

Indian drug maker to get know-how from Gilead Sciences Inc, to manufacture the API for Remdesivir, make the finished product and market it in 127 countries, including India

Robust antibody tests are critical for surveillance and understanding the proportion of the population exposed to SARS Cov-2 infection

Cadila said in its opinion this particular matter is not likely to have any material impact on the operations and financials of the company

The reason for the recall is the presence of foreign tablets

Zydus Pharmaceuticals USA Inc is the US arm of Zydus Cadila's listed entity Cadila Healthcare

The USFDA said the reason for recall is 'out of specification for a known degradant'